PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs. The activation of the downstream receptor pathways was also studied by means of v-akt murine thymoma viral oncogene homolog (AKT), extracellular signal-regulated kinase (ERK), and mammalian target of rapamycin (mTOR) Western blotting experiments, as well as rat sarcoma viral oncogene homolog (RAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), and phosphatase and tensin homolog deleted on chromosome ten (PTEN) mutational analysis and fluorescence in situ hybridization. PDGFRA, PDGFRB, and EGFR were expressed/activated, with higher levels of EGFR expression/phosphorylation paralleling increasing EGFR gene copy numbers in the NF1-related cases (71%). Autocrine loop activation of these receptors along with their coactivation were suggested by the expression of the cognate ligands in the absence of mutations and the presence of receptor tyrosine kinase (RTK) heterodimers, respectively. Both MPNST groups showed AKT, ERK, and mTOR expression/phosphorylation. No BRAF, PI3KCA, or PTEN mutations were found in either group of MPNSTs, but 18% of the sporadic MPNSTs showed RAS mutations. PTEN monosomy segregated with the NF1-related cases (50%, p = 0.018), but PTEN protein was expressed in all but two cases. In conclusion, PDGFRA, PDGFRB, and EGFR seem to be promising molecular targets for tailored treatments in MPNST. In particular, the ligand- and heterodimerization-dependent RTK activation/expression coupled with a downstream signaling phosphorylation, mediated by the upstream receptors or RAS activation, may provide a rationale to apply combined RTK and mTOR inhibitor treatments both to sporadic and NF1-related cases.

[1]  O. Merimsky,et al.  Expression and significance of EGFR in malignant peripheral nerve sheath tumor , 2008, Journal of Neuro-Oncology.

[2]  S. Andreola,et al.  PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. von Deimling,et al.  EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. , 2008, Neuro-oncology.

[4]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[5]  H. Lane,et al.  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors , 2008, Molecular Cancer Therapeutics.

[6]  F. Grosso,et al.  A sporadic multiple GIST with unusual pathologic, molecular, and genetic features. , 2008, The American journal of surgical pathology.

[7]  N. Thomas,et al.  Germline and somatic NF1 gene mutation spectrum in NF1‐associated malignant peripheral nerve sheath tumors (MPNSTs) , 2008, Human mutation.

[8]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[9]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[10]  P. Radice,et al.  Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis , 2007, Clinical Cancer Research.

[11]  C. Hartmann,et al.  MMP-13, p53 in the Progression of Malignant Peripheral Nerve Sheath Tumors , 2007 .

[12]  H. Iwasaki,et al.  Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB , 2007, Laboratory Investigation.

[13]  Silvia Benvenuti,et al.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.

[14]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[15]  P. Nederlof,et al.  EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  A. von Deimling,et al.  MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. , 2007, Neoplasia.

[17]  M. Pierotti,et al.  Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[18]  C. Mussi,et al.  Malignant peripheral nerve sheath tumors , 2006, Cancer.

[19]  G. T. Budd,et al.  Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Casali,et al.  PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma , 2006 .

[21]  A. von Deimling,et al.  Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. , 2006, Carcinogenesis.

[22]  P. Casali,et al.  PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. , 2006, The Journal of pathology.

[23]  J. Stachura,et al.  GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology , 2006, Laboratory Investigation.

[24]  M. Pierotti,et al.  9p21 locus analysis in high‐risk gastrointestinal stromal tumors characterized for c‐kit and platelet‐derived growth factor receptor α gene alterations , 2005, Cancer.

[25]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[26]  J. Declue,et al.  Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. , 2005, Cancer cell.

[27]  U. Pastorino,et al.  Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[28]  F. Grosso,et al.  Imatinib mesylate in chordoma , 2004, Cancer.

[29]  M. Gariboldi,et al.  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.

[30]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[31]  M. Pierotti,et al.  p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  M. Pierotti,et al.  p15 INK4b , p14 ARF , and p16 INK4a Inactivation in Sporadic and Neurofibromatosis Type 1-related Malignant Peripheral Nerve Sheath Tumors 1 , 2003 .

[33]  M. Watson,et al.  Differential NF1, p16, and EGFR Patterns by Interphase Cytogenetics (FISH) in Malignant Peripheral Nerve Sheath Tumor (MPNST) and Morphologically Similar Spindle Cell Neoplasms , 2002, Journal of neuropathology and experimental neurology.

[34]  H. Iwasaki,et al.  Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis , 2002, The Journal of pathology.

[35]  R. Schneider-Stock,et al.  Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors , 2002, Virchows Archiv.

[36]  M. Pierotti,et al.  Rb and TP53 Pathway Alterations in Sporadic and NF1-Related Malignant Peripheral Nerve Sheath Tumors , 2001, Laboratory Investigation.

[37]  G. Benvenuto,et al.  Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. , 2000, The Journal of clinical investigation.

[38]  B. Scheithauer,et al.  Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. , 1999, The American journal of pathology.

[39]  D. Louis,et al.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. , 1999, The American journal of pathology.

[40]  P. Marynen,et al.  TP53 mutations are frequent in malignant NFI tumors , 1994, Genes, chromosomes & cancer.

[41]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[42]  Jeng-Shin Lee,et al.  Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.